TrialPhase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Trial details
- Registry ID
- NCT04417530
- Phase
- Phase 2
AURA
Aura Biosciences
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaNCT04417530 | Aura Biosciences | Phase 2 | Completed | 2024-04-22Actual |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaNCT06007690 | Aura Biosciences | Phase 3 | Active not recruiting | 2027-11-15Estimated |
| Suprachoroidal Administration in Subjects With Metastases to the ChoroidNCT06643884 | Aura Biosciences | Phase 2 | Recruiting | 2026-11-30Estimated |
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Trial details
- Registry ID
- NCT06007690
- Phase
- Phase 3
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Trial details
- Registry ID
- NCT06643884
- Phase
- Phase 2
Latest recorded trial changes
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690 · Aura Biosciences
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
100 participants (planned)
+ After
108 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884 · Aura Biosciences
Primary completion date changed
− Before
31 Mar 2026
+ After
30 Nov 2026
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690 · Aura Biosciences
Primary completion date changed
− Before
1 Mar 2026
+ After
15 Nov 2027
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884 · Aura Biosciences
Primary completion date changed
− Before
31 Jan 2026
+ After
31 Mar 2026
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting